Jinyi Li1,2, Hongyu Kuang3, Xue Zhan4,5. 1. Department of Gastroenterology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. 2. Ministry of Education Key Laboratory of Child Development and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing, China. 3. Department of Cardiology, Children's Hospital of Chongqing Medical University, Chongqing, China. 4. Department of Gastroenterology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. zhanxue@hotmail.com. 5. Ministry of Education Key Laboratory of Child Development and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Chongqing, China. zhanxue@hotmail.com.
Abstract
OBJECTIVES: To evaluate the efficacy and safety of nitazoxanide in intestinal parasitic infections in children. METHODS: Four databases, PubMed, EMBASE, Web of Science and Cochrane Library, have been systematically searched from the inception of each database up to March 1st, 2019. The enrolled studies were limited to randomized clinical trials in children, comparing nitazoxanide with placebo or other antiparasitic drugs. The data extraction and quality assessment of pooled studies were conducted by two reviewers independently. For meta-analysis, Stata12.0 was used and a randomized effect model or a fixed effect model was selected according to the outcomes of heterogeneity test. RESULTS: A total of 1645 subjects in 13 randomized controlled trials (RCTs) were enrolled, including 768 cases in the trial group and 877 cases in the control group. The effect of nitazoxanide vs. placebo and other antiparasitic drugs on the excretion rate of pathogens was uncertain (OR = 2.06, 95%CI [1.01,4.20], P = 0.047; I2 = 84.7%; very low quality evidence). Compared with placebo, subgroup analysis suggested that nitazoxanide could significantly improve the excretion rate of pathogens (OR = 7.01, 95%CI [1.82,26.94], P = 0.005; I2 = 79.1%; moderate quality evidence), while it made little or no difference compared with antiparasitic drugs (OR = 0.72, 95%CI [0.47,1.09], P = 0.124; I2 = 33.1%; low quality evidence). Meanwhile, nitazoxanide might increase the remission rate of diarrhea with OR = 5.12, 95%CI [2.00,13.08], P = 0.001; I2 = 72.3%; low quality evidence). However, it might also increase the rate of adverse events (OR = 1.47, 95%CI [1.05,2.07], P = 0.026; I2 = 44.7%; low quality evidence). CONCLUSIONS: The authors are uncertain whether or not nitazoxanide could improve the excretion rate of pathogens. Based on low-certainty evidence, nitazoxanide may improve the remission rate of diarrhea in children with intestinal parasite infections, but it may be associated with an increased risk of adverse reactions. Hence, more RCTs with a low risk of bias are still needed to assess the efficacy and safety of nitazoxanide.
OBJECTIVES: To evaluate the efficacy and safety of nitazoxanide in intestinal parasitic infections in children. METHODS: Four databases, PubMed, EMBASE, Web of Science and Cochrane Library, have been systematically searched from the inception of each database up to March 1st, 2019. The enrolled studies were limited to randomized clinical trials in children, comparing nitazoxanide with placebo or other antiparasitic drugs. The data extraction and quality assessment of pooled studies were conducted by two reviewers independently. For meta-analysis, Stata12.0 was used and a randomized effect model or a fixed effect model was selected according to the outcomes of heterogeneity test. RESULTS: A total of 1645 subjects in 13 randomized controlled trials (RCTs) were enrolled, including 768 cases in the trial group and 877 cases in the control group. The effect of nitazoxanide vs. placebo and other antiparasitic drugs on the excretion rate of pathogens was uncertain (OR = 2.06, 95%CI [1.01,4.20], P = 0.047; I2 = 84.7%; very low quality evidence). Compared with placebo, subgroup analysis suggested that nitazoxanide could significantly improve the excretion rate of pathogens (OR = 7.01, 95%CI [1.82,26.94], P = 0.005; I2 = 79.1%; moderate quality evidence), while it made little or no difference compared with antiparasitic drugs (OR = 0.72, 95%CI [0.47,1.09], P = 0.124; I2 = 33.1%; low quality evidence). Meanwhile, nitazoxanide might increase the remission rate of diarrhea with OR = 5.12, 95%CI [2.00,13.08], P = 0.001; I2 = 72.3%; low quality evidence). However, it might also increase the rate of adverse events (OR = 1.47, 95%CI [1.05,2.07], P = 0.026; I2 = 44.7%; low quality evidence). CONCLUSIONS: The authors are uncertain whether or not nitazoxanide could improve the excretion rate of pathogens. Based on low-certainty evidence, nitazoxanide may improve the remission rate of diarrhea in children with intestinal parasite infections, but it may be associated with an increased risk of adverse reactions. Hence, more RCTs with a low risk of bias are still needed to assess the efficacy and safety of nitazoxanide.
Authors: P Abboud; V Lemée; G Gargala; P Brasseur; J J Ballet; F Borsa-Lebas; F Caron; L Favennec Journal: Clin Infect Dis Date: 2001-05-09 Impact factor: 9.079
Authors: Cesar E Davila-Gutierrez; Clemente Vasquez; Benjamin Trujillo-Hernandez; Miguel Huerta Journal: Am J Trop Med Hyg Date: 2002-03 Impact factor: 2.345
Authors: Jean-François Rossignol; Samir M Kabil; Yehia El-Gohary; Azza M Younis Journal: Trans R Soc Trop Med Hyg Date: 2007-07-20 Impact factor: 2.184
Authors: Salah M M Hussien; Osama H Abdella; Anwar H Abu-Hashim; Gamal A Aboshiesha; Mohamad A A Taha; Ahmed S El-Shemy; Mohamad M El-Bader Journal: J Egypt Soc Parasitol Date: 2013-08
Authors: Mario A Rodríguez-Pérez; Juan Antonio Pérez-Vega; José Francisco Cen-Aguilar; Rossanna Rodríguez-Canul Journal: Res Rep Trop Med Date: 2011-12-12
Authors: Ivan Müller; Peiling Yap; Peter Steinmann; Bruce P Damons; Christian Schindler; Harald Seelig; Nan S N Htun; Nicole Probst-Hensch; Markus Gerber; Rosa du Randt; Uwe Pühse; Cheryl Walter; Jürg Utzinger Journal: Parasit Vectors Date: 2016-09-05 Impact factor: 3.876